Search Results
Showing 10 of 231 search results for:
BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Biological: PHE885
Eligibility
Ages Eligible for Study : 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 1 of 10
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
Status
Condition
Multiple Myeloma, Amyloidosis
Phase
INTERVENTION
Drug: Lenalidomide, Drug: Pomalidomide
Eligibility
Ages Eligible for Study : 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 2 of 10
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
Status
Condition
Relapsed or Refractory Multiple Myeloma
Phase
INTERVENTION
Drug: Carfilzomib, Drug: Dexamethasone, Drug: Pomalidomide
Eligibility
Ages Eligible for Study : 18 to 99 Years (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 3 of 10
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
Status
Condition
Relapsed/Refractory Multiple Myeloma
Phase
INTERVENTION
Biological: Adult differentiated autologous T-cells with anti-BCMA specificity
Eligibility
Ages Eligible for Study : 18 to 75 Years (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 4 of 10
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Status
Condition
Relapsed or Refractory Multiple Myeloma
Phase
INTERVENTION
Drug: Immediate Release (IR) Formulation, Drug: Gastro-Retentive (GR) Formulation, Drug: Dexamethasone, Drug: Pomalidomide
Eligibility
Ages Eligible for Study : 18 to 100 Years (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 5 of 10
Combination Study for High Risk Multiple Myeloma Patients
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Drug: Elotuzumab, Drug: Pomalidomide, Drug: Carfilzomib, Drug: Dexamethasone
Eligibility
Ages Eligible for Study : 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 6 of 10
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Status
Condition
Mantle-Cell Lymphoma, Indolent B Cell Lymphoma, Primary Mediastin...
Phase
INTERVENTION
Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
Eligibility
Ages Eligible for Study : 18 to 70 Years (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : Yes
Result 7 of 10
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Drug: POM, Drug: Steroids, Drug: PLD, Drug: CFZ, Drug: BTZ, Drug: CLA, Drug: CY
Eligibility
Ages Eligible for Study : 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 8 of 10
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Drug: ACY-241, Drug: Pomalidomide, Drug: Dexamethasone
Eligibility
Ages Eligible for Study : 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 9 of 10
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Drug: Elotuzumab, Drug: Pomalidomide, Drug: Dexamethasone
Eligibility
Ages Eligible for Study : 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 10 of 10